Inhibitex, Inc

Inhibitex, Inc., a development stage company, engages in the discovery, development, and commercialization of novel antibody-based products for the prevention and treatment of serious bacterial and fungal infections. The company, through its MSCRAMM protein platform, develops Aurexis, which completed Phase II clinical trial for the treatment of staphylococcus aureus bloodstream infections in hospitalized patients. Its preclinical product candidates include candida monoclonal antibodies for treatment of candida infections; staphylococcus epidermidis monoclonal antibodies for staphylococcus epidermidis infections; enterococcos monoclonal antibodies for the treatment of enterococcos infections; staphylococcal vaccine for the prevention of staphylococcal infections; and diagnostic products for Staphylococcal infections. The company has collaboration agreements with Wyeth for the development of human staphylococcal vaccines; Dyax Corp. to co-develop monoclonal antibodies to prevent or treat serious infections caused by enterococci; and 3M Company for the development of various diagnostic products. Inhibitex was founded in 1994 and is based in Alpharetta, Georgia.